enGene Therapeutics Inc. (ENGNW) Free cash flow 2022–2025
enGene Therapeutics Inc. (ENGNW) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$100.7MFY2025 · since FY2022: -$17.7M → -$100.7M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$100.7M | -104.7% |
| FY2024 | -$49.2M | -96.3% |
| FY2023 | -$25.1M | -41.2% |
| FY2022 | -$17.7M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice